Medical Device CVD Guide: FDA Compliance & Best Practices

Master Coordinated Vulnerability Disclosure (CVD) for medical devices. Learn FDA requirements, ISO/IEC 29147 standards, and how to handle security researchers.

This guide is written for medical device manufacturers navigating coordinated vulnerability disclosure medical device. It is built from real submissions, FDA correspondence, and the standards reviewers actually cite. Use it as a working reference: read straight through, jump to the section that matches your current gap, or hand it to your engineering and regulatory leads as a checklist.

Introduction to CVD in the Medical Device Sector

Introduction to CVD in the Medical Device Sector is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 250+ device submissions.

Why CVD Matters for Patient Safety

Why CVD Matters for Patient Safety. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

The Shift from 'Hacker' to 'Security Researcher'

The Shift from 'Hacker' to 'Security Researcher'. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

FDA Regulatory Framework for Vulnerability Disclosure

FDA Regulatory Framework for Vulnerability Disclosure is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 250+ device submissions.

Postmarket Management Guidance Overview

Postmarket Management Guidance Overview. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Section 524B and Continuous Monitoring Requirements

Section 524B and Continuous Monitoring Requirements. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

The Role of ISACs and ISAOs in CVD

The Role of ISACs and ISAOs in CVD. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Core Components of an Effective CVD Program

Core Components of an Effective CVD Program is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 250+ device submissions.

The Intake Process: How to Receive Reports

The Intake Process: How to Receive Reports. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Verification and Triage: Determining Severity via CVSS v3.1/v4.0

Verification and Triage: Determining Severity via CVSS v3.1/v4.0. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Remediation Timelines: When to Patch vs. When to Notify

Remediation Timelines: When to Patch vs. When to Notify. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Industry Standards: ISO/IEC 29147 and 30111

Industry Standards: ISO/IEC 29147 and 30111 is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 250+ device submissions.

Applying Cybersecurity Best Practices to Clinical Workflows

Applying Cybersecurity Best Practices to Clinical Workflows. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Adhering to AAMI TIR57 for Risk Management

Adhering to AAMI TIR57 for Risk Management. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Communicating with Stakeholders during Disclosure

Communicating with Stakeholders during Disclosure is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 250+ device submissions.

Working with Security Researchers and 'White Hats'

Working with Security Researchers and 'White Hats'. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Notifying Users, Providers, and Regulatory Bodies

Notifying Users, Providers, and Regulatory Bodies. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

The 'Safe Harbor' Provision for Researchers

The 'Safe Harbor' Provision for Researchers. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Common Pitfalls and How to Avoid Them

Common Pitfalls and How to Avoid Them is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 250+ device submissions.

How Blue Goat Cyber Approaches coordinated vulnerability disclosure medical device

We treat coordinated vulnerability disclosure medical device as a regulated engineering workstream, not a one-time document drop. Every engagement is led by senior medical-device security engineers who have shipped 250+ FDA cybersecurity submissions across 510(k), De Novo, PMA, and EU MDR pathways. Here is how we run it end to end:

• Scoping against your device profile. We baseline connectivity, interfaces, data flows, and intended use before we touch a template - because reviewer expectations for a Class II wearable are not the same as a networked hospital platform.
• Standards mapping in writing. Every deliverable is traced to the February 2026 FDA premarket cybersecurity guidance, AAMI SW96, AAMI TIR57 / TIR97, IEC 81001-5-1, and ISO 14971 - with the citation in the artifact itself so reviewers do not have to guess.
• Evidence generated inside your QMS. Threat models, SBOMs, security risk assessments, and test reports are versioned under design controls so the traceability from requirement → test → residual risk holds up under audit.
• Independent testing where it counts. Penetration testing and vulnerability analysis are executed by a testing team that does not also write the design - the separation FDA reviewers increasingly expect on cyber devices.
• Deficiency-ready posture. We anticipate the RTA, AI-letter, and Major deficiency patterns FDA has issued over the past 24 months and pre-empt them in the initial submission, cutting the odds of a second review cycle.
• Postmarket handoff, not abandonment. Every premarket package leaves you with a working postmarket monitoring plan, CVD process, and update cadence so the evidence you shipped stays defensible after clearance.

If you want that treatment applied to your coordinated vulnerability disclosure medical device package, our FDA Premarket Cybersecurity Services and FDA Cybersecurity Deficiency Response engagements are the two most common entry points.

Frequently asked questions

What is a coordinated vulnerability disclosure (CVD) program for medical devices?

Short answer: coordinated vulnerability disclosure medical device is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using.

What does the FDA require for medical device vulnerability disclosure?

Short answer: coordinated vulnerability disclosure medical device is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using.

How do I report a security vulnerability in a medical device?

Short answer: Treat it as a process, not a one-off document: own the requirement in design controls, map it to a current standard, generate evidence during V&V, and surface the residual risk in your postmarket plan. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using.

What is the difference between CVD and a bug bounty program in healthcare?

Short answer: coordinated vulnerability disclosure medical device is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using.

How long do medical device manufacturers have to disclose a vulnerability?

Short answer: FDA gives sponsors 180 days to respond to a Major deficiency / AI letter (15 days for an RTA hold). Plan for two iteration cycles; teams that ship a clean response in one round are the ones with a working SPDF. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using.

Where this fits in the cluster

This page sits downstream of our pillar resources on coordinated vulnerability disclosure medical device. If you arrived here from a different starting point, these are the most useful adjacent pages:

• FDA Postmarket Cybersecurity Services
• The Postmarket Cybersecurity Readiness Plan
• The SPDF Playbook for FDA-Ready Medical Devices
• Medical Device Penetration Testing

Related from Blue Goat Cyber

• FDA Cybersecurity Deficiency Response
• FDA-Compliant SBOM Services
• 12 Critical Findings from Medical Device Penetration Tests
• Legacy Medical Device Cybersecurity
• Medical Device Threat Modeling

Sources & primary references

• Cybersecurity in Medical Devices: Postmarket Management of Cybersecurity Vulnerabilities. FDA (U.S. Food and Drug Administration)
• Vulnerability Disclosure Guidelines. NIST (National Institute of Standards and Technology)
• CVE-2023-XXXXX Search and Standards. NVD (National Vulnerability Database)
• AAMI TIR57: Principles for medical device security, Risk management. AAMI (Association for the Advancement of Medical Instrumentation)
• ISO/IEC 29147:2018 Information technology. Security techniques. Vulnerability disclosure. ISO/IEC

Talk to a regulatory cybersecurity team

If you are working through coordinated vulnerability disclosure medical device and want a second pair of eyes on your submission package, we ship cybersecurity deliverables for medical device manufacturers across 510(k), De Novo, PMA, and EU MDR pathways. Book a discovery session and we will walk your evidence with you.